By Dean Seal The publicly traded biopharmaceutical company Immunome has agreed to merge with the private biotechnology company Morphimmune in an all-stock.
Biopharmaceutical company Immunome (IMNM) and private biotechnology company Morphimmune announced Thursday that they have entered into a definitive merger agreement to combine in an all-stock transaction.
Shares of biopharmaceutical company Immunome, Inc. (IMNM) are rising more than 36% Thursday morning after announcing merger with Morphimmune, a private biotechnology company in an all-stock transaction.
Immunome, Inc. , a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the. | May 23, 2023